Neither rheumatoid arthritis (RA) nor ankylosing spondylitis (AS) is categorically worse than the other, but they are “worse” in different ways. RA tends to cause more pain, greater physical disability, and higher mortality risk. AS progresses more slowly in terms of work disability but can permanently fuse the spine, creating a different kind of long-term limitation. The honest answer is that severity depends on which aspect of life you’re measuring.
Where Each Disease Attacks
RA and AS target fundamentally different structures in the body, which shapes how each one feels and what it threatens over time.
RA is a disease of the joint lining. It inflames the soft tissue inside joints, particularly the small joints of the hands, wrists, and feet. The inflammation is typically symmetrical, meaning it hits the same joints on both sides of your body. Left unchecked, it erodes bone surfaces and destroys cartilage, gradually deforming the joints.
AS attacks the spine and the spots where tendons and ligaments anchor into bone, particularly around the sacroiliac joints at the base of the spine. Over time, the inflamed vertebrae can generate new bone growth that bridges the gaps between them, eventually fusing sections of the spine into a rigid column. AS can also affect large peripheral joints like the hips and knees, but the spine is the primary battleground.
Who Gets Each Condition
The two diseases strike very different populations. RA affects women about three times as often as men, with onset most common between ages 30 and 60. AS flips that ratio: men are affected roughly three times more often than women, and symptoms usually begin in the late teens or twenties. This earlier onset means people with AS often face decades of disease management during their most productive working years.
Pain and Physical Function
When researchers directly compare how patients rate their own health, RA consistently scores worse. In a study comparing quality-of-life surveys across both diseases, RA patients reported significantly lower physical functioning scores (41.8 out of 100) than AS patients (52.6 out of 100). The gap was even more striking for pain: RA patients scored 30.1 on the bodily pain scale compared to 45.0 for AS patients. On both scales, higher numbers mean better health. The overall physical health summary score was 32.5 for RA versus 37.1 for AS.
These numbers reflect averages, and individual experiences vary enormously. A person with mild RA may function far better than someone with aggressive AS. But across large groups of patients, RA imposes a heavier burden on day-to-day physical life.
Work Disability Over Time
Both diseases carry a real risk of forcing people out of work, but the trajectories differ. A review of cross-sectional studies found that work disability in RA ranged from 13% after about six months of disease to 67% after an average of 15 years. For AS, rates were somewhat lower, ranging from 3% after 8 years to 50% after 45 years of disease.
Data from the British Society for Rheumatology Biologics Register paints a similar picture at a single snapshot: among patients starting biologic therapy, 49.4% of RA patients (with a median disease duration of 11 years) were work disabled, compared to 41.1% of AS patients (median disease duration 13 years). RA erodes working capacity faster, though AS catches up over a longer timeline.
Structural Damage
The type of permanent damage each disease causes is qualitatively different, which makes direct comparison tricky.
RA destroys joints from the inside out. Even patients in clinical remission or low disease activity continue to show radiographic progression. In one Swiss registry study, about 9% of patients in remission and 11% of those in low disease activity showed meaningful bone erosion progression per year. RA can deform fingers, wrists, and feet to the point where basic tasks like gripping or walking become difficult.
AS builds rather than destroys. The new bone growth that bridges vertebrae can lock the spine into a fixed position, often a forward-stooped posture. This fusion is irreversible and, in advanced cases, can restrict chest expansion enough to affect breathing. The hips are another common site of severe structural damage in AS, sometimes requiring joint replacement relatively early in life.
Complications Beyond the Joints
About 40% of RA patients develop complications outside the joints at some point during their disease. The most common include rheumatoid nodules (firm lumps under the skin, present in up to 30% of patients), chronic anemia, and lung involvement. Lung disease linked to RA is particularly concerning: autopsy studies have found evidence of inflammation around the lungs in 50% of cases, though only about 10% are detected clinically during life.
AS has its own set of extra-joint problems. The most common is uveitis, a painful inflammation of the eye that can threaten vision if untreated. Inflammatory bowel disease also occurs at higher rates in people with AS. Both conditions increase cardiovascular risk, but RA carries a particularly well-documented link to heart disease and stroke.
Mortality Risk
RA carries a measurable increase in the risk of premature death. A large meta-analysis covering nearly 500,000 RA patients found a standardized mortality ratio of 1.52, meaning RA patients are about 52% more likely to die in a given period compared to the general population. The excess deaths are driven primarily by cardiovascular disease, respiratory disease, infections, and stroke. This increased risk holds regardless of sex or geographic region.
AS also shortens life expectancy, though the data is less robust and the effect appears smaller. The primary mortality concerns in AS are cardiovascular disease and complications from spinal rigidity, including fractures in a fused spine that can be catastrophic because the spine behaves more like a long bone than a flexible column.
Treatment Response
Both diseases are treated with similar classes of medications, including conventional disease-modifying drugs and newer biologics that target specific immune pathways. However, the treatment landscape differs in important ways.
RA has more approved treatment options, and the goal of therapy is remission, which is achievable for a meaningful percentage of patients, especially when treatment starts early. Conventional drugs like methotrexate remain effective first-line therapy for many RA patients, with biologics reserved for those who don’t respond adequately.
AS responds poorly to conventional disease-modifying drugs. Exercise and physical therapy are foundational treatments, and biologics play a more central role earlier in the treatment course. Among biologic-naive AS patients, response rates (defined as 40% improvement on a standardized scale) range from about 39% to 54% depending on the specific drug. Patients who have already failed one biologic see lower response rates, between 9% and 40%. These numbers reflect meaningful improvement, not remission, and many AS patients continue to have significant symptoms despite treatment.
Diagnosis Delays
One area where AS is clearly “worse” is the time it takes to get a correct diagnosis. AS symptoms, particularly chronic low back pain starting in young adulthood, overlap with extremely common conditions and are often dismissed for years. Average diagnostic delays of 7 to 10 years have been reported in many studies, though this gap is narrowing with better awareness and MRI availability.
RA can also take time to diagnose, with one study finding an average of about 30 months from the first doctor visit to a final RA diagnosis, with patients seeing an average of four physicians along the way. Still, RA’s more recognizable pattern of swollen, symmetrical joint inflammation typically leads to diagnosis faster than AS.
Which Is Worse Overall
If you’re comparing average disease burden across large populations, RA edges out AS on most measurable outcomes: worse pain scores, lower physical function, faster work disability, higher mortality risk, and more systemic complications. But this framing misses what makes AS uniquely difficult. The years-long diagnostic delay, the onset during young adulthood, the irreversible spinal fusion, and the limited response to conventional medications all create a distinct kind of hardship that doesn’t show up neatly in summary scores.
Severity in both diseases exists on a wide spectrum. Mild RA with early treatment can be far less disabling than aggressive AS that goes undiagnosed for a decade. The most meaningful comparison isn’t between the two diagnoses in the abstract, but between how well each is controlled in a specific person, which depends on how early it’s caught, how aggressively it’s treated, and how well the individual responds to available therapies.